From Symptom Management to Disease Treatment

Our multi-asset approach and screening platform are designed to move efficiently from idea to clinic

Pipeline
We develop RNA-targeting ASOs to slow or reverse disease progression in chronic neurological disorders

Clinical trials of our lead asset for epliepsy are set to start in 2026

Compound
NMT.001
NMT.002
NMT.003
NMT.004
Target
miR-134
‍Undisclosed
Undisclosed
Undisclosed
Indication
Epilepsy
Parkinson's Disease
Undisclosed
Undisclosed
Screening
Dose range
Disease PoC
IND Filing
Phase 1/2a
Development platform
We develop RNA-targeting ASOs to slow or reverse disease progression in chronic neurological disorders

‍

24-36 months from target ID to clinical testing
Target ID
ASO Design
In Vitro Screening
Lead ID
Lead OP
In Vivo PoC
CMC Tox/PK
Phase 1
Phase 2
Phase 3
Registration

Work with us

Interested in joining Neumirna? Explore current career opportunities or contact us to learn how you can contribute to our mission.

Learn more